These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7518099)

  • 1. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits.
    Matthiasson SE; Lindblad B; Mätzsch T; Holst J; Bergqvist D
    Thromb Haemost; 1994 Mar; 71(3):363-5. PubMed ID: 7518099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of experimental venous thrombosis in rabbits with low molecular weight heparin, dextran and their combinations, administered before or during induction of venous endothelial trauma.
    Matthiasson SE; Lindblad B; Bergqvist D
    Thromb Res; 1994 Jun; 74(6):655-63. PubMed ID: 7522356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model.
    Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JL; Nielsen G; Hedner U
    Haemostasis; 1993 Mar; 23 Suppl 1():112-7. PubMed ID: 8495862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep.
    Matthiasson SE; Bergqvist D; Lundell A; Lindblad B
    Eur J Vasc Endovasc Surg; 1995 Apr; 9(3):284-92. PubMed ID: 7542544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
    Schumacher WA; Heran CL; Steinbacher TE
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370.
    Colucci M; Rossiello MR; Barbanti M; Calanni F; Semeraro N
    Thromb Haemost; 1998 Aug; 80(2):338-41. PubMed ID: 9716163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.
    Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JG; Nielsen G; Hedner U
    Thromb Haemost; 1994 Feb; 71(2):214-9. PubMed ID: 8191401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?
    Holst J; Lindblad B; Nordfang O; Ostergaard PB; Hedner U
    Haemostasis; 1996; 26(1):23-30. PubMed ID: 8698275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on the antithrombotic efficacy of hirudin, heparin and a low-molecular weight heparin in preventing experimentally induced venous thrombosis.
    Monreal M; Galego G; Monreal L; Angles AM; Monasterio J; Oller B
    Haemostasis; 1993; 23(3):179-83. PubMed ID: 8276322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin.
    Matthiasson SE; Lindblad B; Bergqvist D
    Haemostasis; 1995; 25(3):124-32. PubMed ID: 7607580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats.
    Farina JA; Piccinato CE; Campos AD; Rossi MA
    Microsurgery; 2006; 26(6):456-64. PubMed ID: 16924631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of platelet inhibition on experimental venous thrombosis in the rabbit.
    Bergqvist D; Björck CG; Esquivel C; Nilsson B
    Acta Chir Scand; 1985; 151(5):429-31. PubMed ID: 2413666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of volume expanders on the lysability of ex vivo thrombi in the rabbit.
    Esquivel CO; Bergqvist D; Björck CG; Nilsson B; Bergentz SE
    Acta Chir Scand; 1982; 148(4):359-62. PubMed ID: 6182722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of heparin, low molecular weight (LMW) heparin, and a heparin analogue on experimental venous thrombosis in the rabbit.
    Björck CG; Bergqvist D; Esquivel C; Nilsson B; Rudsvik Y
    Acta Chir Scand; 1984; 150(8):629-33. PubMed ID: 6085202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model.
    Giedrojć J; Krupiński K; Breddin HK; Bielawiec M
    Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
    Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
    J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat.
    Salartash K; Gonze MD; Leone-Bay A; Baughman R; Sternbergh WC; Money SR
    J Vasc Surg; 1999 Sep; 30(3):526-31. PubMed ID: 10477646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextran's antithrombotic properties in small arteries are not altered by low-molecular-weight heparin or the fibrinolytic inhibitor tranexamic acid: an experimental study.
    Zhang B; Wieslander JB
    Microsurgery; 1993; 14(4):289-95. PubMed ID: 7692212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.